Erin Bastick
Erin Bastick is a PharmD Candidate 2016, Ohio Northern University, Ada, Ohio, and an inpatient intern at University Hospitals, Cleveland.
FDA approves new Onsolis formulation
FDA has approved sNDA for new formulation of fentanyl buccal soluble film (Onsolis, BioDelivery Sciences International) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant.
Skin cancer drug Odomzo gets FDA approval
FDA has approved sonidegib (Odomzo, Novartis) for locally advanced basal cell carcinoma.
FDA approves Technivie for treatment of hepatitis C virus genotype 4 infections
FDA has approved ombitsavir, paritaprevir and ritonavir (Technivie, AbbVie) for the treatment of hepatitis C virus genotype 4 infections.
FDA grants first-ever CLIA waiver to herpes test, system
FDA has granted CLIA waiver to Theranos for herpes simplex virus test and test system.
FDA approves Orkambi for treatment of cystic fibrosis
FDA has approved lumacaftor/ivacaftor (Orkambi, Vertex) for the treatment of cystic fibrosis in patients 12 years and older.
FDA OKs antiplatelet for use during heart procedure
FDA has approved cangrelor (Kengreal, The Medicines Company) for reducing the risk of periprocedural thrombotic events in patients undergoing percutaneous coronary intervention.
Promacta stimulates platelet production in cITP pediatric patients
FDA has approved eltrombopag (Promacta, Novartis) for the treatment of children aged 6 years and older with chronic immune thrombocytopenia.
FDA grants priority review to expand use of Brilinta
The FDA has granted Priority Review for ticagrelor (Brilinta, AstraZeneca) for patients with a history of heart attack.
Drug approved for rare, lung disease that strikes younger women
Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women of childbearing age. The FDA has approved sirolimus (Rapamune, Pfizer) as the first drug to treat LAM. Rapamune was originally approved to prevent organ rejection.
Pediatric migraine drug gets FDA green light
FDA has approved sumatriptan and naproxen sodium (Treximet, Pernix Therapeutics) for the treatment of migraines in pediatric patients.